鹿得医疗：Q3收入和净利润同比增速回升

Investment Rating - The report assigns a neutral investment rating to the company, indicating that its performance is expected to align with the market index over the next 12 months [8]. Core Insights - The company specializes in cardiovascular monitoring products, respiratory therapy products, and home health care products, utilizing a combination of self-manufactured and externally sourced components for its production [1]. - For the first nine months of 2024, the company reported revenues of 234.68 million yuan, a year-on-year decrease of 1.44%, and a net profit attributable to shareholders of 18.40 million yuan, down 29.99% year-on-year [4]. - In the third quarter of 2024, the company achieved revenues of 86.95 million yuan, reflecting a year-on-year increase of 12.19%, with a net profit of 6.51 million yuan, up 0.45% year-on-year [4]. - The company maintained strict cost control, with a gross margin of 25.07% for the first nine months of 2024, down 2.96 percentage points year-on-year, and a net margin of 7.84%, down 3.20 percentage points year-on-year [4]. Financial Summary - As of November 8, 2024, the company's closing price was 9.20 yuan, with a total share capital of 176 million shares and a net asset value of 390.62 million yuan [2]. - The company's earnings per share for 2023 was 0.18 yuan, with a price-to-earnings ratio of 48.10 [5].